IL179408A0 - Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors - Google Patents

Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors

Info

Publication number
IL179408A0
IL179408A0 IL179408A IL17940806A IL179408A0 IL 179408 A0 IL179408 A0 IL 179408A0 IL 179408 A IL179408 A IL 179408A IL 17940806 A IL17940806 A IL 17940806A IL 179408 A0 IL179408 A0 IL 179408A0
Authority
IL
Israel
Prior art keywords
bicyclic
nitrogen
aromatase inhibitors
containing heterocycles
heterocycles
Prior art date
Application number
IL179408A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of IL179408A0 publication Critical patent/IL179408A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL179408A 2004-05-28 2006-11-20 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors IL179408A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH9152004 2004-05-28
PCT/EP2005/052416 WO2005118540A2 (en) 2004-05-28 2005-05-27 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors

Publications (1)

Publication Number Publication Date
IL179408A0 true IL179408A0 (en) 2007-05-15

Family

ID=34968588

Family Applications (2)

Application Number Title Priority Date Filing Date
IL179408A IL179408A0 (en) 2004-05-28 2006-11-20 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
IL179406A IL179406A0 (en) 2004-05-28 2006-11-20 Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL179406A IL179406A0 (en) 2004-05-28 2006-11-20 Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors

Country Status (10)

Country Link
US (2) US20080076784A1 (OSRAM)
EP (2) EP1749005A1 (OSRAM)
JP (2) JP5179174B2 (OSRAM)
CN (2) CN1960991A (OSRAM)
AR (2) AR049125A1 (OSRAM)
BR (2) BRPI0511621A (OSRAM)
CA (2) CA2568163A1 (OSRAM)
IL (2) IL179408A0 (OSRAM)
TW (2) TW200616623A (OSRAM)
WO (2) WO2005118540A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568163A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
AR049667A1 (es) * 2004-07-09 2006-08-23 Speedel Experimenta Ag Heterociclos condensados conteniendo n como inhibidores de aromatasa y procedimiento para prepararlos
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
AR060225A1 (es) * 2006-03-31 2008-06-04 Speedel Experimenta Ag Proceso para preparar 6,7- dihidro-5h-imidazo (1,5-a) piridin -8- ona
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
PL2319923T3 (pl) * 2008-07-24 2014-05-30 Meiji Seika Pharma Co Ltd Geny biosyntezy pirypiropenu A
ES3050068T3 (en) * 2008-11-07 2025-12-19 Univ Of Sheffield Medicament and method of diagnosis
NZ596159A (en) 2009-05-13 2014-03-28 Meiji Seika Pharma Co Ltd Process for producing pyripyropene derivatives
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
US8519134B2 (en) * 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
UA111151C2 (uk) 2010-03-01 2016-04-11 Мейдзі Сейка Фарма Ко., Лтд. Спосіб одержання похідних пірипіропену
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CN103958478B (zh) * 2011-11-30 2017-08-01 霍夫曼-拉罗奇有限公司 双环二氢异喹啉‑1‑酮衍生物
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
RU2016116433A (ru) * 2013-10-17 2017-11-22 Ф. Хоффманн-Ля Рош Аг Новые производные фенил-дигидропиридина в качестве ингибиторов альдостерон синтазы
CA2918195A1 (en) * 2013-10-17 2015-04-23 F. Hoffmann-La Roche Ag Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
AU2018230521B2 (en) 2017-03-10 2022-02-03 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
CN117659075B (zh) * 2023-12-18 2025-02-11 中国科学院兰州化学物理研究所 一种咪唑衍生型柱[5]芳烃手性填料的制备及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
JPH0670064B2 (ja) 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
EP0625155B1 (en) * 1992-01-27 2001-08-08 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
WO1997000257A1 (en) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US6333335B1 (en) * 1999-07-23 2001-12-25 Merck & Co., Inc. Phenyl-protein transferase inhibitors
JP2001151696A (ja) * 1999-11-22 2001-06-05 Keiko Tanaka アクチニジンから造る腫瘍の増殖ならびに転移抑制酵素と異質なたんぱく細胞の除去剤
EP1681290B9 (en) * 2000-11-17 2013-06-19 Takeda Pharmaceutical Company Limited Imidazole derivatives, production method thereof and use thereof
AR049388A1 (es) 2004-05-28 2006-07-26 Speedel Experimenta Ag Heterociclos como inhibidores de aldosterona sintasa
CA2568163A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds

Also Published As

Publication number Publication date
US20070225232A1 (en) 2007-09-27
WO2005118540A3 (en) 2006-02-02
CA2568163A1 (en) 2005-12-15
CN1960991A (zh) 2007-05-09
JP2008500997A (ja) 2008-01-17
IL179406A0 (en) 2007-05-15
CA2568159A1 (en) 2005-12-15
AR049125A1 (es) 2006-06-28
EP1749005A1 (en) 2007-02-07
CN1968930A (zh) 2007-05-23
JP2008501000A (ja) 2008-01-17
BRPI0511621A (pt) 2008-01-02
BRPI0510409A (pt) 2007-10-23
EP1765777A2 (en) 2007-03-28
JP5179174B2 (ja) 2013-04-10
AR049126A1 (es) 2006-06-28
WO2005118540A2 (en) 2005-12-15
TW200616623A (en) 2006-06-01
TW200612947A (en) 2006-05-01
US20080076784A1 (en) 2008-03-27
US8680079B2 (en) 2014-03-25
WO2005118581A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
IL179408A0 (en) Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
GB2424882B (en) Selective kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
IL181720A0 (en) Bicyclic amides as kinase inhibitors
EP1928237A4 (en) NEW HETEROCYCLES BASED ON IMIDAZO
ZA200703079B (en) DNA-PK Inhibitors
IL180587A0 (en) Heterocyclic compounds
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL205159A0 (en) Imidazole compounds
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
EP1880993A4 (en) NITROGENIC HETEROCYCLIC COMPOUND
IL183276A0 (en) Kinase inhibitors
IL179305A0 (en) Dpp-iv inhibitors
ZA200607648B (en) Kinase inhibitors
ZA200608775B (en) Monocyclic heterocycles as kinase inhibitors
ZA200700650B (en) Bicyclic amides as kinase inhibitors
GB0421355D0 (en) Inhibitors
EP1799653A4 (en) NEW HETEROCYCLES
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
IL190277A0 (en) Aril-substituted nitrogen-containing heterocyclic compound
GB0421356D0 (en) Inhibitors
HK1102964A (en) Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors